Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET

Background and Objectives To predict when cognitively normal individuals with brain amyloidosis will develop symptoms of Alzheimer disease (AD). Methods Brain amyloid burden was measured by amyloid PET with Pittsburgh compound B. The mean cortical standardized uptake value ratio (SUVR) was transformed into a timescale with the use of longitudinal data. Results Amyloid accumulation was evaluated in 236 individuals who underwent >1 amyloid PET scan. The average age was 66.5 ± 9.2 years, and 12 individuals (5%) had cognitive impairment at their baseline amyloid PET scan. A tipping point in amyloid accumulation was identified at a low level of amyloid burden (SUVR 1.2), after which nearly all individuals accumulated amyloid at a relatively consistent rate until reaching a high level of amyloid burden (SUVR 3.0). The average time between levels of amyloid burden was used to estimate the age at which an individual reached SUVR 1.2. Longitudinal clinical diagnoses for 180 individuals were aligned by the estimated age at SUVR 1.2. In the 22 individuals who progressed from cognitively normal to a typical AD dementia syndrome, the estimated age at which an individual reached SUVR 1.2 predicted the age at symptom onset (R2 = 0.54, p < 0.0001, root mean square error [RMSE] 4.5 years); the model was more accurate after exclusion of 3 likely misdiagnoses (R2 = 0.84, p < 0.0001, RMSE 2.8 years). Conclusion The age at symptom onset in sporadic AD is strongly correlated with the age at which an individual reaches a tipping point in amyloid accumulation.

[1]  Keith A. Johnson,et al.  Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation , 2020, Neurology.

[2]  D. Minhas,et al.  Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories , 2020, Neurobiology of Aging.

[3]  F. Alkuraya Faculty Opinions recommendation of Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[4]  Bertrand Morel,et al.  Early mechanisms of amyloid fibril nucleation in model and disease-related proteins. , 2019, Biochimica et biophysica acta. Proteins and proteomics.

[5]  Sterling C. Johnson,et al.  Amyloid duration is associated with preclinical cognitive decline and tau PET , 2019, bioRxiv.

[6]  A. Srivastava,et al.  β‐Amyloid aggregation and heterogeneous nucleation , 2019, Protein science : a publication of the Protein Society.

[7]  A. Fagan,et al.  Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network , 2019, Neurobiology of Aging.

[8]  Andrei G. Vlassenko,et al.  Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies , 2019, Alzheimer's & dementia.

[9]  A. Fagan,et al.  Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers , 2018, Brain : a journal of neurology.

[10]  J. Dukart,et al.  Rate of β-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials , 2018, Alzheimer's & Dementia.

[11]  Yi Su,et al.  Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE &egr;4 genotype , 2018, Brain : a journal of neurology.

[12]  Chengjie Xiong,et al.  Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies , 2018, NeuroImage: Clinical.

[13]  E. Mormino,et al.  APOE genotype and early β-amyloid accumulation in older adults without dementia , 2017, Neurology.

[14]  C A Budgeon,et al.  Constructing longitudinal disease progression curves using sparse, short‐term individual data with an application to Alzheimer's disease , 2017, Statistics in medicine.

[15]  Chengjie Xiong,et al.  The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model , 2017, Alzheimer's & Dementia.

[16]  Chengjie Xiong,et al.  Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease , 2016, Annals of neurology.

[17]  Jerry L. Prince,et al.  Individual estimates of age at detectable amyloid onset for risk factor assessment , 2016, Alzheimer's & Dementia.

[18]  Michael J Leach,et al.  Longitudinal , 2015, The Medical journal of Australia.

[19]  Jerry L Prince,et al.  Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts , 2015, Neurobiology of Aging.

[20]  Karen M Rodrigue,et al.  Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.

[21]  D. Holtzman,et al.  Three dimensions of the amyloid hypothesis: time, space and 'wingmen' , 2015, Nature Neuroscience.

[22]  Keith A. Johnson,et al.  Partial volume correction in quantitative amyloid imaging , 2015, NeuroImage.

[23]  Nick C Fox,et al.  Symptom onset in autosomal dominant Alzheimer disease , 2014, Neurology.

[24]  H. Soininen,et al.  Harmonized diagnostic criteria for Alzheimer's disease: recommendations , 2014, Journal of internal medicine.

[25]  Y. Stern Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.

[26]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[27]  Andrei G. Vlassenko,et al.  Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data , 2011, Annals of neurology.

[28]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[29]  W. Klunk,et al.  Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ε4 Genotype in Alzheimer's Disease , 2010, Biological Psychiatry.

[30]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[31]  J. Morris,et al.  The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers , 2006, Alzheimer disease and associated disorders.

[32]  J Philip Miller,et al.  Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI , 2006, Neurology.

[33]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[34]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  J. Miller,et al.  Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. , 1993, Archives of neurology.

[36]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[37]  J. Morris,et al.  Clinicopathologic study of Alzheimer's disease: Alzheimer mimics. , 2013, Journal of Alzheimer's disease : JAD.

[38]  G. Bedoya,et al.  Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. , 2003, Annals of neurology.

[39]  P. Lansbury,et al.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.